Compare ITRG & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ITRG | BOLD |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 576.2M | 60.8M |
| IPO Year | 2017 | 2024 |
| Metric | ITRG | BOLD |
|---|---|---|
| Price | $2.82 | $2.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $5.13 | $4.00 |
| AVG Volume (30 Days) | ★ 2.7M | 233.9K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $67.34 | N/A |
| Revenue Next Year | $25.89 | N/A |
| P/E Ratio | $45.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.99 | $0.96 |
| 52 Week High | $4.87 | $3.16 |
| Indicator | ITRG | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 62.88 | 59.74 |
| Support Level | $2.68 | $2.71 |
| Resistance Level | $2.86 | $2.97 |
| Average True Range (ATR) | 0.13 | 0.13 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 70.00 | 30.56 |
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.